熱門資訊> 正文

Trevi Therapeutics任命新首席财务官

2025-12-04 20:43

Trevi Therapeutics (TRVI) named David Hastings as its next chief financial officer, effective January 6, 2026.
Hastings prior roles include CFO positions at Arbutus, Unilife, and Incyte.
Hastings currently serves on the board and chairs the audit committee of Scynexis.

More on Trevi Therapeutics

Trevi Therapeutics: "Buy" Rating For Haduvio Treating Chronic Cough In IPF And Beyond
Trevi Therapeutics: Big Cough Data, Bigger Execution Risk
Trevi Therapeutics, Inc. (TRVI) Q3 2025 Earnings Call Transcript
Trevi Therapeutics edges higher amid takeover speculation
Trevi Therapeutics targets multiple phase III trial launches for chronic cough indications in 2026 as regulatory plans accelerate

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。